DISOPYRAMIDE PHOSPHATE

Disopyramide phosphate is an organoammonium phosphate. 
Disopyramide phosphate belongs to a group of medicines called anti-arrhythmic agents used to treat irregular heartbeats.
Disopyramide phosphate is available in both oral and intravenous forms and has a low degree of toxicity.

CAS Number: 3737-09-5
Formula: C21H29N3O
Molar mass: 339.483 g·mol−1

Disopyramide phosphate is an antiarrhythmic chemical used in the treatment of ventricular tachycardia.
Disopyramide phosphate is a sodium channel blocker and is classified as a Class 1a anti-arrhythmic agent.

Disopyramide phosphate has a negative inotropic effect on the ventricular myocardium and significantly reduces contractility.
Disopyramide phosphate also has an anticholinergic effect on the heart, which is responsible for many negative side effects.
Disopyramide phosphate is available in both oral and intravenous forms and has a low degree of toxicity.

Disopyramide phosphate is registered under the REACH Regulation and is manufactured in and / or imported to the European Economic Area, for intermediate use only.
Disopyramide phosphate is used at industrial sites and in manufacturing.

Disopyramide phosphate is an organoammonium phosphate. 

Disopyramide phosphate phosphate is a class Ia antiarrhythmic agent with cardiac depressant properties. 
Disopyramide phosphate phosphate exerts Disopyramide phosphate actions by blocking both sodium and potassium channels in cardiac membrane during phase 0 of the action potential. 

This slows the impulse conduction through the AV node and prolongs the duration of the action potential of normal cardiac cells in atrial and ventricular tissues. 
Disopyramide phosphate prolongs the QT interval and causes a widening of the QRS complex. 

Disopyramide phosphate also possesses some anticholinergic and local anaesthetic properties. 
Disopyramide phosphate phosphate is used in the treatment of supraventricular tachycardia.

A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. 
Disopyramide phosphate also possesses some anticholinergic and local anesthetic properties.

Disopyramide phosphate belongs to a group of medicines called anti-arrhythmic agents used to treat irregular heartbeats.
An irregular heartbeat is a condition in which your heart beats irregularly, too fast, or too slow.
Disopyramide phosphate helps slow the heart rate and prevent arrhythmias (abnormal heart rhythms).

Disopyramide phosphate contains Disopyramide phosphate, ie anti-arrhythmic agents.
Disopyramide phosphate helps bring irregular heartbeats to a normal rhythm by blocking certain electrical signals in the heart.
Irregular heartbeat treatment reduces the risk of blood clots, heart attack or stroke.

Disopyramide phosphate should be taken as prescribed by the doctor.
Your doctor may monitor EKGs and blood pressure during treatment to monitor your dose.

Some people may experience common side effects such as blurred or double vision, stomach pain, little or no urination, and low blood sugar.
Most of these side effects of Disopyramide phosphate do not require medical attention and will gradually improve over time.
However, if the side effects persist, please consult your doctor.

Please tell your doctor if you are known to be allergic to Disopyramide phosphate or any other medicines.
Disopyramide phosphate is not recommended for use in children. 
Pregnant or breastfeeding women are advised to consult a doctor before taking Disopyramide phosphate.

Before taking Disopyramide phosphate, tell your doctor if you have kidney or liver disease, enlarged prostate, glaucoma (increased eye pressure) or low potassium levels in the blood (hypokalaemia).
Do not take Disopyramide phosphate if you are already taking other medicines to regulate your heartbeat.

Do not drive or operate machinery as Disopyramide phosphate may cause blurred vision, dizziness and low blood pressure.
Use Disopyramide phosphate with caution if you are elderly (over 65 years of age), have a low body weight, or have kidney or liver problems.

Disopyramide phosphate is used to treat certain irregular heartbeats).
Disopyramide phosphate is in a class of medications called antiarrhythmic drugs.
Disopyramide phosphate works by making your heart more resistant to abnormal activity.

Continuing Education Activity:
Disopyramide phosphate is a chemical used to treat heart rhythm abnormalities that can be life-threatening, such as ventricular tachycardia/fibrillation, or associated with increased morbidity and mortality, such as atrial fibrillation and hypertrophic cardiomyopathy.
This activity reviews several important aspects of this chemical, including indications, mechanism of action, applications, side effects, contraindications, monitoring, and toxicity.
This important knowledge of this chemical can improve interprofessional healthcare team outcomes.

Objectives:
Describe the mechanism of action of Disopyramide phosphate.
Describe possible side effects of Disopyramide phosphate.

Explains the importance of monitoring when using Disopyramide phosphate as an antiarrhythmic chemical.
Outline professional team strategies for improving care coordination and communication when using Disopyramide phosphate to maximize the benefits of this chemical and minimize Disopyramide phosphate side effects.

Indications:
In 1962, new antiarrhythmic drugs were needed apart from quinidine and procainamide, which were the main antiarrhythmic agents available at the time.
Disopyramide phosphate is the selected agent among more than 500 compounds synthesized for the research program of new antiarrhythmic agents.
The chemical structures of Disopyramide phosphate are similar to the synthetic muscarinic antagonist lacquer, which explains Disopyramide phosphate anticholinergic property.

Although Disopyramide phosphate is rarely used for heart rhythm abnormalities due to the availability of newer drugs that provide better efficacy and favorable side-effect profiles, Disopyramide phosphate is still the drug of choice for vagal-mediated atrial fibrillation such as sleep-induced or atrial fibrillation in athlete groups.
The effectiveness of Disopyramide phosphate in these conditions is due to Disopyramide phosphate anticholinergic activity, which abolishes the parasympathetic tone.

Disopyramide phosphate is also a third-line antiarrhythmic agent for a patient with coronary artery disease.
Also, a patient with left ventricular hypertrophy has impaired depolarization, which can induce torsade de pointes.

Therefore, antiarrhythmics that prolong the QT interval are avoided, but if sotalol or amiodarone is unsuccessful or unsuitable, Disopyramide phosphate may be an alternative.
In a patient with atrial fibrillation and hypertrophic obstructive cardiomyopathy (HOCM), Disopyramide phosphate is the agent of choice, other than amiodarone, as Disopyramide phosphate may decrease the left ventricular outflow tract (LVOT) gradient (off-label use).

Data from a multicenter study of the safety and efficacy of Disopyramide phosphate in obstructive cardiomyopathy showed that Disopyramide phosphate significantly reduced the SVOT gradient from 75+/- 33 to 40+/-32 mmHg in 78 patients (66% of study subjects) (P<0.0001). has shown. ) and raises the New York Heart Association functional class (NYHA FC) from 23+/-07 to 17+/-06 (P<0.0001).
When Disopyramide phosphate is used in combination with a non-dihydropyridine calcium channel blocker or beta blocker, they can effectively prevent recurrence of AF in HCOM patients.

Patients with ventricular premature beat (VPB) or premature ventricular complexes (PVC) may have a high symptom burden.
Disopyramide phosphate can be used in patients without structural heart disease, although Disopyramide phosphate efficacy is less than ablation.
In addition, based on a randomized, double-blind, placebo-controlled one-year follow-up study, Disopyramide phosphate (n=44) was effective in maintaining sinus rhythm after electro cardioversion for atrial fibrillation compared to placebo (n=46) and was significantly different (%) at one-month follow-up. 70 vs 39%) and continues after twelve months (54% vs 30%).

Uses of Disopyramide phosphate:
Disopyramide phosphate is used to treat certain types of serious (possibly fatal) irregular heartbeat (such as sustained ventricular tachycardia). 
Disopyramide phosphate is used to restore normal heart rhythm and maintain a regular, steady heartbeat. 

Disopyramide phosphate is known as an anti-arrhythmic drug. 
Disopyramide phosphate works by blocking certain electrical signals in the heart that can cause an irregular heartbeat. 
Treating an irregular heartbeat can decrease the risk for blood clots, and this effect can reduce your risk of heart attack or stroke.

Usage of Disopyramide phosphate:
Disopyramide phosphate comes as a capsule and an extended-release (long-acting) capsule to take by mouth. 
Disopyramide phosphate capsules may be taken every 6 or 8 hours. 

The extended-release capsule is usually taken every 12 hours. 
Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. 

Take Disopyramide phosphate exactly as directed. 
Do not take more or less of Disopyramide phosphate or take it more often than prescribed by your doctor.

Swallow the extended-release capsules; do not open, crush, or chew them.

Disopyramide phosphate helps control your condition but will not cure it. 
Continue to take Disopyramide phosphate even if you feel well. 
Do not stop taking Disopyramide phosphate without talking to your doctor.

Mechanism of action of Disopyramide phosphate:
Disopyramide phosphate's Class 1a activity is similar to that of quinidine in that Disopyramide phosphate targets sodium channels to inhibit conduction.
Disopyramide phosphate depresses the increase in sodium permeability of the cardiac myocyte during Phase 0 of the cardiac action potential, in turn decreasing the inward sodium current. 

This results in an increased threshold for excitation and a decreased upstroke velocity.
Disopyramide phosphate prolongs the PR interval by lengthening both the QRS and P wave duration.

This effect is particularly well suited in the treatment of ventricular tachycardia as Disopyramide phosphate slows the action potential propagation through the atria to the ventricles. 
Disopyramide phosphate does not act as a blocking agent for beta or alpha adrenergic receptors, but does have a significant negative inotropic effect on the ventricular myocardium.
As a result, the use of Disopyramide phosphate may reduce contractile force up to 42% at low doses and up to 100% in higher doses compared to quinidine.

Levites proposed a possible secondary mode of action for Disopyramide phosphate, against reentrant arrhythmias after an ischemic insult. 
Disopyramide phosphate decreases the inhomogeneity between infarcted and normal myocardium refractory periods; in addition to lengthening the refractory period.

This decreases the chance of re-entry depolarization, because signals are more likely to encounter tissue in a refractory state which cannot be excited.
This provides a possible treatment for atrial and ventricular fibrillation, as Disopyramide phosphate restores pacemaker control of the tissue to the SA and AV nodes.

Pharmacology and Biochemistry of Disopyramide phosphate:

MeSH Pharmacological Classification:

Anti-Arrhythmia Agents:
Agents used for the treatment or prevention of cardiac arrhythmias. 
They may affect the polarization-repolarization phase of the action potential, Disopyramide phosphate excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. 
Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Obstructive hypertrophic cardiomyopathy:
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, occurring in 1:500 individuals in the general population. 
Disopyramide phosphate is estimated that there are 600,000 individuals in the United States with hypertrophic cardiomyopathy. 

The most common variant of HCM presents with left ventricular (LV) intracavitary obstruction due to systolic anterior motion of the mitral valve, and mitral-septal contact, diagnosed readily with echocardiography. 
Pharmacologic treatment with negative inotropic drugs is first-line therapy. 

Beta-blockers are used first, and while they improve symptoms of shortness of breath, chest pain and exercise intolerance, they do not reduce resting LV intraventricular pressure gradients and often are inadequate to control symptoms. 
Many investigators and clinicians believe that Disopyramide phosphate controlled release is the most potent agent available for reducing resting pressure gradients and improving symptoms.

Disopyramide phosphate has been actively used for more than 30 years.
Disopyramide phosphate administration for obstructive HCM has a IB recommendation in the 2020 American Heart Association/American College of Cardiology Foundation guidelines for treatment of obstructive HCM.
A IB treatment recommendation indicates that a treatment is recommended, and may be useful, and beneficial.

Negative inotropes improve LV obstruction by decreasing LV ejection acceleration and hydrodynamic forces on the mitral valve. 
Disopyramide phosphate's particular efficacy is due to Disopyramide phosphate potent negative inotropic effects; in head-to-head comparison, Disopyramide phosphate is more effective for gradient reduction than either beta-blocker or verapamil.

Disopyramide phosphate is most often administered with beta-blockade. 
When used in patients resistant to beta-blockade, Disopyramide phosphate is effective in 60% of cases, reducing symptoms and gradient to the extent that invasive procedures such as surgical septal myectomy are not required.

Disopyramide phosphate, despite Disopyramide phosphate efficacy, has one main side effect that has limited Disopyramide phosphate use in the US, though Disopyramide phosphate has seen wider application in Canada, UK and Japan. 
Vagal blockade predictably causes dry mouth, and in men with prostatism, may cause urinary retention. 
Teichman et al. showed that pyridostigmine used in combination with Disopyramide phosphate substantially alleviates vagolytic side effects without compromising antiarrhythmic efficacy.

This combination has also been shown to be effective and safe in obstructive HCM in a large cohort of patients.
Some clinicians prescribe pyridostigmine sustained release (marketed in the US as Mestinon Timespan) to every patient begun on Disopyramide phosphate.
This combination increases acceptance of higher Disopyramide phosphate dosing, important since there is a dose-response correlation in obstructive HCM, higher doses yielding lower gradients.

Another concern about Disopyramide phosphate has been the hypothetical potential for inducing sudden death from Disopyramide phosphate type 1 anti-arrhythmic effects. 
However, a multicenter registry and two recent cohort registries have largely reduced this concern, by showing sudden death rates lower than that observed from the disease itself.

These concerns about the drug must be viewed from the clinical perspective that Disopyramide phosphate is generally the last agent that is tried for patients before they are referred for invasive septal reduction with surgical septal myectomy (an open-heart operation) or alcohol septal ablation (a controlled heart attack). 
Both of these invasive procedures have risk of morbidity and mortality.

For selected patients, a trial of oral Disopyramide phosphate is a reasonable approach before proceeding to invasive septal reduction. 
Patients who respond to Disopyramide phosphate are continued on the drug. 

Those who continue to have disabling symptoms or who experience side effects are promptly referred for septal reduction. 
Using such a stepped strategy, investigators have reported that survival does not differ from that observed in the age-matched normal United States population.

Extracardiac effects:
Atropine like effects (anticholinergic)
Dry mouth
Constipation
Urinary retention – Disopyramide phosphate should not be given to patients with symptomatic prostatism.
Blurred vision
Glaucoma
Rash
Agranulocytosis

Additionally, Disopyramide phosphate may enhance the hypoglycaemic effect of gliclazide, insulin, and metformin.

Metabolism of Disopyramide phosphate:
Disopyramide phosphate can cause hypoglycemia, perhaps due to increased secretion of insulin, and can also potentiate the effects of conventional hypoglycemic drugs. 
This effect may be due to Disopyramide phosphate chief metabolite mono-N dealkylDisopyramide phosphate, since many of the reported cases of hypoglycemia have been in patients with renal impairment, in which the metabolite accumulates. 

In six subjects who were being considered for treatment with Disopyramide phosphate, serum glucose concentrations were measured at 13, 15, 17, and 19 hours after supper, with no further food, with and without the added administration of two modified-released tablets of Disopyramide phosphate 150 mg with supper and 12 hours later. 
Disopyramide phosphate significantly reduced the serum glucose concentration at all measurement times by an average of 0.54 mmol/l. 
The fall in serum glucose concentration was not related to the serum concentration of Disopyramide phosphate or the serum creatinine concentration; Disopyramide phosphate was greater in older patients and in underweight patients.

Hypoglycemia has also been reported in a 70-year-old woman with type 2 diabetes mellitus taking Disopyramide phosphate.

Clinical data of Disopyramide phosphate:
Trade names: Norpace
AHFS/Drugs.com: Monograph
MedlinePlus: a682408
Pregnancy category: AU: B2
Routes ofadministration: Oral, intravenous
ATC code: C01BA03 (WHO)

Legal status:
UK: POM (Prescription only)
US: ℞-only

Pharmacokinetic data of Disopyramide phosphate:
Bioavailability: High
Protein binding: 50% to 65% (concentration-dependent)
Metabolism: Hepatic (CYP3A4-mediated)
Elimination half-life: 6.7 hours (range 4 to 10 hours)
Excretion: Renal (80%)

Identifiers of Disopyramide phosphate:
IUPAC name: (RS)-4-(Diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide
CAS Number: 3737-09-5
PubChem CID: 3114
IUPHAR/BPS: 7167
DrugBank: DB00280
ChemSpider: 3002
UNII: GFO928U8MQ
KEGG: D00303
ChEBI: CHEBI:4657
ChEMBL: ChEMBL517
CompTox Dashboard (EPA): DTXSID1045536
ECHA InfoCard: 100.021.010

Properties of Disopyramide phosphate:
Formula: C21H29N3O
Molar mass: 339.483 g·mol−1
Melting point: 94.5 to 95 °C (202.1 to 203.0 °F)
SMILES: O=C(N)C(c1ncccc1)(c2ccccc2)CCN(C(C)C)C(C)C
InChI: InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
Key:UVTNFZQICZKOEM-UHFFFAOYSA-N

Molecular Weight: 437.5 g/mol
Hydrogen Bond Donor Count: 4
Hydrogen Bond Acceptor Count: 7
Rotatable Bond Count: 8
Exact Mass: 437.20795813 g/mol
Monoisotopic Mass: 437.20795813 g/mol
Topological Polar Surface Area: 137Ų
Heavy Atom Count: 30
Complexity: 459
Isotope Atom Count: 0
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count: 1
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Covalently-Bonded Unit Count: 2
Compound Is Canonicalized: Yes

Names of Disopyramide phosphate:

Regulatory process names:
Disopyramide
Disopyramide

IUPAC names:
4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide
4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide
Disopyramide

Other identifiers:
3737-09-5

Synonyms of Disopyramide phosphate:
Disopyramide PHOSPHATE
22059-60-5
Norpace
Disopyramide PHOSPHATE SALT
Rythmodan
Norpace Cr
SC 7031 phosphate
Dirythmin sa
Diso-duriles
DisopyramidePhosphate
EINECS 244-756-1
SC 7031 (phosphate)
NSC-756744
SC-13957
SC-7031 PHOSPHATE
CHEBI:4658
N6BOM1935W
22059-60-5 (phosphate)
SC 13957
Norpace (TN)
2-(1-(Ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)pyridinium phosphate
Disopyramid phosphate
4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide phosphate
4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide;phosphoric acid
alpha-(2-Diisopropylaminoethyl)-alpha-phenyl-2-pyridineacetamide phosphate
(+-)-alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate (1:1)
2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, phosphate
2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, phosphate (1:1)
2-Pyridineacetamide, alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-, phosphate
alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide phosphate (1:1)
2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, (+-)-, phosphate (1:1)
SR-01000003039
Disopyramide (phosphate)
UNII-N6BOM1935W
SCHEMBL41810
MLS000028431
SPECTRUM1500261
C21H29N3O.H3O4P
CHEMBL1201020
HMS501I11
DTXSID30944685
Disopyramide phosphate (JAN/USP)
HMS1920I14
HMS2094K15
HMS2234B16
HMS3259J21
HMS3261C04
HMS3369L05
HMS3652M20
HMS3885J07
Pharmakon1600-01500261
Disopyramide PHOSPHATE [MI]
XAA05960
Disopyramide PHOSPHATE [JAN]
Tox21_500411
CCG-40209
Disopyramide PHOSPHATE [USAN]
HY-12533A
NSC756744
Disopyramide PHOSPHATE [VANDF]
AKOS040744844
Disopyramide PHOSPHATE [MART.]
Disopyramide PHOSPHATE [USP-RS]
Disopyramide PHOSPHATE [WHO-DD]
LP00411
NC00683
NSC 756744
Disopyramide phosphate [USAN:BAN:JAN]
NCGC00093836-01
NCGC00093836-02
NCGC00093836-03
NCGC00093836-04
NCGC00261096-01
SMR000058438
Disopyramide PHOSPHATE [ORANGE BOOK]
LS-130131
Disopyramide PHOSPHATE [EP MONOGRAPH]
Disopyramide phosphate [USAN:USP:BAN:JAN]
EU-0100411
FT-0630479
S4143
SW196836-3
SW196836-4
Disopyramide PHOSPHATE [USP MONOGRAPH]
C07740
D 6035
D00637
SR-01000003039-2
SR-01000003039-6
Q27106430
4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butanamide
(R)-4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide phosphate
4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide,phosphoric acid
4-DIISOPROPYLAMINO-2-PHENYL-2-(2-PYRIDYL)BUTYRAMIDE PHOSPHATE
Disopyramide phosphate, European Pharmacopoeia (EP) Reference Standard
Disopyramide phosphate, United States Pharmacopeia (USP) Reference Standard
(+/-)-.ALPHA.-(2-(DIISOPROPYLAMINO)ETHYL)-.ALPHA.-PHENYL-2-PYRIDINEACETAMIDE PHOSPHATE (1:1)
2-PYRIDINEACETAMIDE, .ALPHA.-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-.ALPHA.-PHENYL-, (+/-)-, PHOSPHATE (1:1)
223-110-2 [EINECS]
2-pyridineacetamide, a-[2-[bis(1-methylethyl)amino]ethyl]-a-phenyl-
2-Pyridineacetamide, α-(2-(bis(1-methylethyl)amino)ethyl)-α-phenyl-
2-Pyridineacetamide, α-[2-[bis(1-methylethyl)amino]ethyl]-α-phenyl- [ACD/Index Name]
3737-09-5 [RN]
4-(Diisopropylamino)-2-phenyl-2-(2-pyridinyl)butanamid [German] [ACD/IUPAC Name]
4-(Diisopropylamino)-2-phenyl-2-(2-pyridinyl)butanamide [ACD/IUPAC Name]
4-(Diisopropylamino)-2-phényl-2-(2-pyridinyl)butanamide [French] [ACD/IUPAC Name]
4-(Diisopropylamino)-2-phenyl-2-(2-pyridyl)butyramide
4-(Diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide
4-(dipropan-2-ylamino)-2-phenyl-2-(pyridin-2-yl)butanamide
a-[2-(Diisopropylamino)ethyl]-a-phenyl-2-pyridineacetamide
a-[2-[Bis(1-methylethyl)amino]ethyl]a-phenyl-2-pyridineacetamide
disopiramida [Spanish] [INN]
Disopyramide [French] [INN]
Disopyramide [BAN] [INN] [JAN] [JP15] [USAN] [Wiki]
Disopyramide, (R)-
Disopyramide, (S)-
disopyramidum [Latin] [INN]
Isorythm
Lispine
MFCD00057366 [MDL number]
Norpace [Trade name]
Rythmodan [Trade name]
α-[2-(DIISOPROPYLAMINO)ETHYL]-α-PHENYL-2-PYRIDINEACETAMIDE
α-Diisopropylaminoethyl-α-phenylpyridine-2-acetamide
дизопирамид [Russian] [INN]
ديسوبيراميد [Arabic] [INN]
丙吡胺 [Chinese] [INN]
Disopyramide free base
NORPACE CR
Rythmodan-La
ξ-Disopyramide
[3737-09-5] [RN]
1309283-08-6 [RN]
2-Pyridineacetamide, α-(2-(diisopropylamino)ethyl)-α-phenyl-
2-Pyridineacetamide, α-[2-(diisopropylamino)ethyl]-α-phenyl-
2-Pyridineacetamide, α-[2-[bis(1-methylethyl)amino]ethyl]-α-phenyl-
3737-09-5 (free base)
38236-46-3 [RN]
4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butanamide
4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide
4-[bis(methylethyl)amino]-2-phenyl-2-(2-pyridyl)butanamide
4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide
4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanimidic acid
4-[di(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide
4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
492056 [Beilstein]
4-Diisopropylamino-2-phenyl-2-(2-pyridyl)-butyramide
54687-36-4 [RN]
74464-83-8 [RN]
74464-84-9 [RN]
BS-17145
DB00280
Dicorantil
Disopiramida
Disopiramida [INN-Spanish]
Disopyramide-d5
Disopyramidum
Disopyramidum [INN-Latin]
MFCD00069254 [MDL number]
n-desalkyl Disopyramide
Norpace®
Ritmodan
Rythmodan P [Trade name]
Rythmodan®
Searle 703
α-(2-(Diisopropylamino)ethyl)-α-phenyl-2-pyridineacetamide
α-(2-(Diisopropylamino)ethyl)-α-phenyl-2-pyridineacetamide
α-[2-[bis(1-methylethyl)amino]ethyl]-α-phenyl-2-pyridineacetamide
γ-Diisopropylamino-α-phenyl-α-(2-pyridyl)butyramide
γ-Diisopropylamino-α-phenyl-α-(2-pyridyl)butyramide
дизопирамид
ديسوبيراميد
丙吡胺